27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Novavax Inc (NASDAQ: NVAX) said that participants in its ongoing COVID-19 vaccine trials in South Africa and the U.K. could receive additional shots, ensuring those who received a placebo can also get the active vaccine.
- Allowing volunteers to crossover to the active vaccine will enable participants to continue in trials and remain blinded.
- The company said it planned to cross over participants in its ongoing large, late-stage study in the U.S. and Mexico. The company plans to read out initial clinical data during the second quarter.
- As part of the updated trial protocol, all participants in the U.K. and the U.S. will be offered the chance to receive an additional round of shots, the company said.
- Participants who opt to do so will receive two additional doses of either vaccine for those who initially received placebo or placebo for those who first got the vaccine.
- Price Action: NVAX shares are trading 4.2% lower at $178 in the premarket session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!